Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Thyroid Neoplasms × sacituzumab govitecan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 17 Triple Negative Breast Neoplasms 12 Carcinoma, Non-Small-Cell Lung 5 Lung Neoplasms 4 Carcinoma, Transitional Cell 4 Urinary Bladder Neoplasms 3 Neoplasm Metastasis 3 Brain Neoplasms 3 Salivary Gland Neoplasms 2 Uterine Cervical Neoplasms 1 Urothelial Bladder Carcinoma 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Recurrence 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Oropharyngeal Neoplasms 1 Neoplasms 1 Neoplasm, Residual 1 Mouth Neoplasms 1 Metastatic Urothelial Cancer 1 Laryngeal Neoplasms 1 Klatskin Tumor 1 Hypopharyngeal Neoplasms 1 HER2-negative Breast Cancer 1 Glioblastoma 1 Esophageal Squamous Cell Carcinoma 1

Interventions

Sorafenib 8 lenvatinib 6 Everolimus 6 trametinib 5 dabrafenib 5 vandetanib 4 pembrolizumab 4 Sunitinib 4 Paclitaxel 4 Nivolumab 4 Magnetic Resonance Spectroscopy 4 Iodine-131 4 selpercatinib 3 apatinib 3 anlotinib 3 surufatinib 2 pazopanib 2 Vemurafenib 2 Triiodothyronine 2 Thyroxine 2 Thyrotropin Alfa 2 Surgical Procedures, Operative 2 Ipilimumab 2 Iodine-124 2 Doxorubicin 2 Docetaxel 2 Cyclophosphamide 2 Biopsy, Large-Core Needle 2 Axitinib 2 AZD 6244 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06923826 2025-07-25

TROP2

National University Hospital, Singapore

Phase 2 Recruiting

Salivary Gland Neoplasms, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡